University of California, San Diego
Division of University of California
Latest From University of California, San Diego
Medicxi-funded Impact Biomedicines gave Sanofi a stake in the start-up to acquire fedratinib and bring the JAK2 inhibitor, which was placed on a clinical hold in 2013, to patients who are out of options.
With promising preclinical data for lead candidate ST1 in ovarian cancer, Siamab thinks therapeutics targeting tumor-associated carbohydrate antigens will offer potential in multiple solid tumor types.
Biomarkers for psychiatric disorders are lacking, but Astellas is investing in its own and external efforts to identify drug targets as well as patients who'll respond to new therapies.
As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.